Mylan launches generics of Vidaza injection, Rythmol capsules

PITTSBURGH — Mylan on Thursday launched two new generic products. The company rolled out its generic of Celgene’s Vidaza (azacitidine, 100 mg/vial) injection and its generic of GSK’s Rhythmol (propafenone HCl) extended-release capsules. 

 

Vidaza is indicated to treat the five French-American-British subtypes of myelodysplastic syndrome, a blood cell disorder that can be the result of cancer treatments or can progress to leukemia. It had sales of approximately $236.3 million in the U.S. for the 12 months ended March 31, according to IMS Health. 

 

Rythmol is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic AF who don’t have structural heart disease. The drug had U.S. sales of about $100.5 million for the 12 months ended March 31, according to IMS Health. Mylan’s generic will be available in 225-, 325- and 425-mg dosage strengths.